Using Artificial Intelligence to Classify ICU Patients According to Risk of Deterioration
Dr. Ofer Chen, VP Clinical Development Clew Medical

- **Investment Rational**
  With growing demand for capacity and for flexibility in its supply, TeleICU solutions virtually monitoring numerous patients are increasingly needed. Clew has developed a TeleICU platform based on AI predictive models, supporting intensivists workflow and clinical decisions. Based on real-time physiological data, these models allow risk classification of ICU patients, enabling prioritization of treatment and reducing false alarm rate.

- **Business Strategy**
  CLEW's FDA-approved solution is currently installed in several hospitals in the US. Being installed either on premises or in the cloud, installation (and ongoing updates) can be performed remotely. The system is user friendly and intuitive, requiring very short training. Hospitals are charged for the installation, as well as a license per ICU bed per year.

- **Core Technology**
  Using machine learning and data science, CLEW develops physiological predictive models based on streaming clinical data from individual patients, identifying patients predicted for hemodynamic or respiratory deteriorations. A designated platform aggregates data to support clinicians' workflow. Probability for deterioration is calculated in near real time per patient, allowing for prompt recognition and timely medical interventions, thus improving patients' outcomes.

- **Product Profile/Pipeline**
  Clew's FDA/CE-approved solution and fully commercial solution is now offered to leading hospitals and providers in the US. In addition, the company (collaborating with Sheba Medical Center) currently develops a predictive analytics-based Clinical Control Tower platform, to help hospital leadership increase capacity and patient throughput, make better informed clinical decisions, improve outcomes and safety, and remove discharge barriers.

- **What's Next?**
  Clew's current **R&D** focus is on both customizing its solutions to customers feedback, while concurrently expending its offering outside the ICU via the Clinical Control Tower. **Structurally**, the company expands its US-based team to support sales, support and customer success. Central upcoming **research** goals are focusing on outcomes in healthcare facilities adopting and using the platform.